If you are referring to the large number at close those are most likely MOC orders being put in at the close.Common to all stocks.If you check you will see many large orders at market close and settled.It is a order you put in 15 min before close and then it is locked in and you cannot change it and you get the settled price at market close.I use them but you have to know what your doing as a stock can go really down seconds before close and if it does may mean more trouble..But overall they have very little for example 500000 shares trade really no indication of the next day.Just depends on how one may think it with the smaller orders we have been seein with moc's we I think have a good chance of a big gap up coming up one of these mornings.
Moo I was thinking about you guys today,Hope all is going well.I even looked at NBG too,lol.I was up on my mountain in montana gettin ready to sell all my Montana land.My partners been a pain in the a.. but I convinced them my way or the highway,so being highly intelligent they went with me.I got them to finally price it reasonably.I was going to pop over and get some ONVO but I been buyin this stock and am going to tie some more up.The last time right around my last post over there I was posting it at I think 2 bucks and it headed over 3.Will do that again it is huge buyout target.Get some,lol.
No.I am a pain patient and can tell you I have been told remoxy they think is going to be really good and marketed.The doctors will be prescribing it.
Why don’t everyone trust these guys? They are awesome – 500% from my first two trades Ultimate Stock Alerts (search them in Google)
I am up 900% thanks to the last pick I got from Ultimate Stock Alerts (look them up in Google)
2) Another micro-cap partner, Pain Therapeutics, Inc. (NASDAQ: PTIE), is expected to re-submit its Remoxy NDA in the first quarter of next year, and the analysts at Cantor believe the drug could get partnered before this occasion.
With respect to REMOXY, Pain Therapeutics (PTIE) is now back in full-control of the asset as of April 2015, recently reported positive top-line data from an abuse potential study in May 2015, and has plans to file the NDA to the U.S. FDA during the first quarter of 2016. We believe that REMOXY represents a $500-750 million drug, of which Durect is entitled to 6-11.5% royalties on commercial sales once launched.
Sentiment: Strong Buy
To all on this board that are bulls - thank- you for turning me on to PTIE - I am good at doing DD, and this is a huge winner !
I have another one that is starting to move that I have done the DD on - AMDA - check it out - this was a busted IPO last year that came public at over $5.00/share last year - the tutes have destoyed it over the recent past - they are almost certain to get FDA 510 K approval very soon !
Thank-you for turning me on to PTIE ! I listened to the May 12th conf. call, and I cannot believe how good it sounds - to have Pfizer do 90% of the work on the lead drug and then give full rights back to PTIE is going to make for a blockbuster - the tutes that have been selling are wrong, wrong ! Drug abuse is very high on FDA's list - and according to the CEO they want multiple players - and the market is huge ! And the CEO answered the most important question - Pfizer is developing a competing drug they acquired through a previous acquisition - but the key is PTIE is the leader in this field !